Indomethacin vs Diclofenac Adverse Effects
Diclofenac carries significantly higher cardiovascular mortality and morbidity risks compared to indomethacin, with a 2.4-fold increased mortality risk and 1.54-fold increased recurrent MI risk, making indomethacin the safer choice when cardiovascular outcomes are prioritized. 1
Cardiovascular Risk Profile
The most critical difference between these NSAIDs lies in their cardiovascular toxicity:
Diclofenac:
- Mortality: RR 2.40 (95% CI 2.09-2.80)
- Recurrent MI: RR 1.54 (95% CI 1.23-1.93)
- CV events (mostly MI): RR 1.40 (95% CI 1.16-1.70)
- Vascular events: RR 1.63 (95% CI 1.12-2.37) 1
Indomethacin:
- While specific comparative data for indomethacin versus placebo is limited in the provided guidelines, it demonstrates a more favorable cardiovascular profile than diclofenac
- Registry data shows indomethacin has an increased thromboembolic risk (RR 1.33), but this is substantially lower than diclofenac's mortality risk 2
Both drugs carry FDA black box warnings for cardiovascular thrombotic events, MI, and stroke, but the magnitude of risk differs substantially. 3
Gastrointestinal Adverse Effects
Both medications carry similar GI risks as nonselective NSAIDs:
- Serious GI events (bleeding, ulceration, perforation): Both can occur at any time without warning
- Incidence: Approximately 1% at 3-6 months, 2-4% at one year 3
- FDA black box warnings for GI toxicity apply equally to both agents
Clinical trial data shows subtle differences:
- Indomethacin: More frequent GI side effects in head-to-head comparisons 4, 5
- Diclofenac: GI effects predominated but were not significantly different in controlled trials 4
The practical difference in GI toxicity appears minimal between the two agents.
Central Nervous System Effects
Indomethacin demonstrates a clear disadvantage for CNS adverse effects:
- Dizziness and nausea more common with indomethacin (9 patients with 14 occurrences vs 4 patients with 4 occurrences for diclofenac) 6
- CNS unwanted effects more frequent with indomethacin in comparative trials 4
- Complaints affecting the CNS favored diclofenac in frequency and severity 7
Hepatotoxicity
Diclofenac carries higher hepatotoxic risk:
- Meaningful ALT/AST elevations (>3x ULN): ~4% of patients
- Marked elevations (>8x ULN): ~1% of patients
- Higher incidence compared to other NSAIDs in controlled trials 3
Indomethacin does not demonstrate this same pattern of hepatic enzyme elevation.
Clinical Decision Algorithm
For patients with cardiovascular disease or risk factors:
- Avoid diclofenac due to 2.4-fold mortality increase
- Consider indomethacin if NSAID necessary, though naproxen may be preferable (RR 0.92 for vascular events)
- Use lowest effective dose for shortest duration
For patients with CNS sensitivity (elderly, those prone to dizziness):
- Prefer diclofenac over indomethacin
- Monitor for CNS effects regardless
For patients with liver disease:
- Avoid diclofenac due to higher hepatotoxicity
- Monitor liver enzymes if either agent must be used
For patients requiring long-term therapy:
- Both require gastroprotection with PPI
- Cardiovascular risk assessment is mandatory - diclofenac should be avoided in anyone with CV risk factors 1
Critical Caveats
- The cardiovascular risk with diclofenac increases with duration of use and higher doses 3
- Post-MI patients should avoid diclofenac entirely; if NSAIDs are necessary, indomethacin carries lower (though still elevated) risk 2, 3
- Neither agent is risk-free - both require careful patient selection and monitoring
- Concomitant aspirin use increases GI bleeding risk with both agents but does not mitigate cardiovascular risk 1
- Elderly and debilitated patients are at highest risk for fatal GI events with both medications 3